Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Stephen L. Hauser(University of California, San Francisco), James Overell(Roche (Switzerland)), Stanislas Hubeaux(University Hospital of Basel), Ludwig Kappos(University Hospital of Basel), Annette Sauter(Inserm), Douglas L. Arnold(McGill University), Robert T. Naismith(Washington University in St. Louis), Harold Koendgen(Roche (Switzerland)), Bruno Brochet(Université de Bordeaux), Marianna Manfrini(University Hospital of Basel), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Hans-Peter Hartung(The University of Sydney), Iain Bennett(Roche (Switzerland))
Cited by 150
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k